Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1448162

GTEX

bdbf189e-fb35-5d7a-b22c-b2a47a877c1b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • NOTCH_SIGNALING+0.312
  • FATTY_ACID_METABOLISM+0.302
  • KRAS_SIGNALING_DN+0.300
  • ADIPOGENESIS+0.268
  • MYOGENESIS+0.268
  • APICAL_SURFACE+0.266
  • BILE_ACID_METABOLISM+0.211
  • CHOLESTEROL_HOMEOSTASIS+0.206
  • XENOBIOTIC_METABOLISM+0.199
  • HEDGEHOG_SIGNALING+0.196

Top 10 suppressed

  • MYC_TARGETS_V2-0.407
  • MYC_TARGETS_V1-0.383
  • UNFOLDED_PROTEIN_RESPONSE-0.379
  • PROTEIN_SECRETION-0.353
  • E2F_TARGETS-0.343
  • G2M_CHECKPOINT-0.338
  • MITOTIC_SPINDLE-0.317
  • DNA_REPAIR-0.293
  • IL6_JAK_STAT3_SIGNALING-0.254
  • TGF_BETA_SIGNALING-0.211

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1409305
brain-umap@2
GTEX—0.880
2SRR1405485
brain-umap@2
GTEX—0.836
3SRR1394755
brain-umap@2
GTEX—0.831
4SRR1418837
brain-umap@2
GTEX—0.803
5SRR655435
brain-umap@2
GTEX—0.798
6TCGA-KQ-A41P-01A-12R-A33J-07
bladder-landscape@3
——0.796
7BS_CVGFNCBJ
brain-umap@2
low-grade glioma—0.796
8ERR2208930
melanoma-umap@29
——0.794
960c210ff-d245-40d2-9de9-7b799cc3ffc9
melanoma-umap@29
——0.792
10BS_AKRHBPNZ
brain-umap@2
Ganglioglioma—0.791

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
NOTCH_SIGNALING0.312Inavolisib— uncovered
FATTY_ACID_METABOLISM0.302Inavolisib— uncovered
KRAS_SIGNALING_DN0.300Remibrutinib— uncovered
ADIPOGENESIS0.268Inavolisib— uncovered
MYOGENESIS0.268Inavolisib— uncovered
APICAL_SURFACE0.266Temsirolimus— uncovered
BILE_ACID_METABOLISM0.211Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.206Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.199Inavolisib— uncovered
HEDGEHOG_SIGNALING0.196Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.183Inavolisib— uncovered
ANGIOGENESIS0.160Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.126Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.105Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.104Cobimetinib— uncovered
HYPOXIA0.095Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.094Inavolisib— uncovered
GLYCOLYSIS0.078Inavolisib— uncovered
P53_PATHWAY0.068Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.063Inavolisib— uncovered